Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Oncogene - 2 Jun 2011

Normant E, Paez G, West K A, Lim A R, Slocum K L, Tunkey C, McDougall J, Wylie A A, Robison K, Caliri K, Palombella V J, Fritz C C

Abstract excerpt

Heat shock protein 90 (Hsp90) is an emerging target for cancer therapy due to its important role in maintaining the activity and stability of key oncogenic signaling proteins. We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion pro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Benzoquinones
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to Oncogene Proteins, Fusion

Share to Receptor, ErbB-2

Share to Serine Endopeptidases

Source

Identifiers

PMID: 21258415
DOI: 10.1038/onc.2010.625

Genes

ALK
EML4
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21258415-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.PMID 21258415Read ↗

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsSemantic proximity Read ↗

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.Semantic proximity Read ↗

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.Semantic proximity Read ↗

HSP90 inhibitors in lung cancer: promise still unfulfilled.Semantic proximity Read ↗

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer DrugsSemantic proximity Read ↗

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitorsSemantic proximity Read ↗

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.Semantic proximity Read ↗

HSP90: A promising target for NSCLC treatments.Semantic proximity Read ↗

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveriesSemantic proximity Read ↗

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effectsSemantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.